Composition comprising combination of rapamycin and metformin and use thereof for treating neoplastic diseases
AssigneeJMM Licensing LLC
InventorJeffrey M. Melin
Life of this patent
Estimating the term…
Abstract
A formulation for treating neoplastic diseases, including post-transplant malignancies, genetically-driven neoplasia associated with mTORC1 hyperactivation, and a viral associated malignancy comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. A method of treating neoplastic diseases comprising administering the formulation comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1.
Claims20
A method of treating a neoplastic disease or disorder comprising administering an effective amount of a composition comprising a combination of rapamycin and metformin to a subject, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1.
A method of treating a neoplastic disease or disorder mediated by mTORC1 activation comprising administering an effective amount of a composition comprising a combination of rapamycin and metformin to a subject, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1.
Dependencies are inferred from the claim text.